DGAVP (Org 5667) in early Alzheimer's disease patients: an international double-blind, placebo-controlled, multicenter trial

E C Wolters; P Riekkinen; A Lowenthal; J J Van der Plaats; J M Zwart; C Sennef

doi:10.1212/wnl.40.7.1099

DGAVP (Org 5667) in early Alzheimer's disease patients: an international double-blind, placebo-controlled, multicenter trial

Neurology. 1990 Jul;40(7):1099-101. doi: 10.1212/wnl.40.7.1099.

Authors

E C Wolters¹, P Riekkinen, A Lowenthal, J J Van der Plaats, J M Zwart, C Sennef

Affiliation

¹ Department of Neurology, Amsterdam Free University, The Netherlands.

PMID: 2192301
DOI: 10.1212/wnl.40.7.1099

Abstract

We carried out a double-blind study of a vasopressin-related peptide, DGAVP citrate (Org 5667), in 115 patients with mild dementia, probable Alzheimer's type (DAT). Neither clinical rating scales nor psychometric tests revealed any improvement over 84 days with once-daily intranasal treatment with 2 different doses of DGAVP. We conclude that vasopressin-like peptides are not satisfactory therapeutic agents in DAT.

Publication types

Clinical Trial
Multicenter Study
Randomized Controlled Trial

MeSH terms

Aged
Aged, 80 and over
Alzheimer Disease / drug therapy*
Alzheimer Disease / physiopathology
Arginine Vasopressin / analogs & derivatives*
Arginine Vasopressin / therapeutic use
Chi-Square Distribution
Double-Blind Method
Humans
Middle Aged
Multicenter Studies as Topic
Psychiatric Status Rating Scales
Randomized Controlled Trials as Topic

Substances

Arginine Vasopressin
argipressin, des-GlyNH2(9)-